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years. The data bases used were PubMed/MEDLINE and
EMBASE. Also, Spanish magazines not indexed in MEDLINE
were reviewed. A review about growth of cost-utility published
studies and other about threshold of the health technology in
Spain, both were included too. Abstracts of Medtronic therapies
and other health technology and devices enterprises were
reviewed. Costs were in euros of the year 2007. RESULTS:
Thirty-one studies with cost/QALY ratio were identiﬁed, 22 of
drug therapies and 8 of diagnostic and therapeutic devices. Cost/
QALY ratio of drug therapies oscillated between -€25.937
(Dasatinib in patients resistant to imatimab in myeloid leukemia)
and €72,583 (Pneumococcal vaccine vs. no vaccine in patients
5–24 years). In diagnostic and therapeutic devices cost/QALY
ratio was between -€30,664 (DES vs. BMS) and €34.389 (Sub-
thalamus stimulation vs. conventional medical therapy in
advanced Parkinson). CONCLUSIONS: In the reviewed studies,
diagnostic and therapeutic devices were cost-effective with a cost
per QALY relation under or near the efﬁciency threshold usually
accepted in Spain. This relation in some cases was lower than
drug therapies used in the usual clinical practice.
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OBJECTIVES: To determine if there are regional market access
inequalities for innovative antineoplastic and immunomodula-
tory drugs (AID) in Spain. METHODS: All new AIDs introduced
in Spain were identiﬁed between 2002 and 2007. AID units
adjusted by population and region were analyzed by means of the
IMS Health Databases: EMF, EMH, and EMHEMF. The time
horizon considered was 12 months prior to September 2007
(MAT 09/07). Regions were the minimal geographic unit allowed
by the databases in order to ensure the representativeness of the
data (I: Aragon, Catalonia, Balearic Islands; II: Valencia, Murcia;
III: Andalusia, Canary Islands; IV: Castile la Mancha, Extrema-
dura, Madrid; V: Asturias, Castile-Leon, Galicia, Navarra,
Basque Country, La Rioja, Cantabria). RESULTS: In Spain,
between January 2002 and October 2007, 16 AIDs were
approved. For methodological limitations only ten drugs were
analyzed: three hospital diagnostic (HD) (imatinib, erlotinib y
sorafenib), six hospital use (H) (alemtuzumab, bortezomib, beva-
cizumab, cetuximab, ibritumomab and pemetrexed) and 1
medical prescription (fulvestrant). HD drugs showed high vari-
ability in units per in-habitant between regions. Erlotinib pre-
sented a 27.7% Standard Deviation (SD) between zones,
concentrating the 69% in zone I. The 31% was distributed
uniformly in the other regions. Imatinib presented a 25% SD,
zone I and V covered the 53.6% and 40.3% of the units
respectively. Sorafenil presented less geographic variation
(SD = 10.1%). Regional differences between hospital drugs were
smaller. SD oscillated between 9.8% (bevacizumab) and 5.3%
(pemetrexed). Zone II presented the highest market share. When
analysing fulvestrant, zones I and V concentrated the 60.9% of
the units and the inter-regional SD was 13.6%. CONCLU-
SIONS: There are important regional inequalities in the number
of units per in-habitant sold for new AIDs. Zones I and V
presented the highest market share whereas in the other zones
market access is highly restricted.
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OBJECTIVES: On the February 15, 2007 new forms of
co-payment were introduced in Hungary: visit fee (300 HUF/
visit) in the outpatient care and hospital daily fee (300 HUF/day)
in the inpatient care. The aim of this study is to analyze the effect
of the introduction of hospital daily fee on the number of inpa-
tient admissions to acute care hospital wards in Hungary
METHODS: The data derive from the ﬁnancial database of the
National Health Insurance Fund Administration (OEP) of
Hungary covering the period of 2006–2008. We analyzed the
number of admissions during a 10 months period before (from
March 2006 to January 2007) and after (from March 2007 to
January 2008) the introduction of daily fee. Data from February
2007 were omitted. RESULTS: During the 10 months period
before the introduction of hospital daily fee the total number of
admissions was 2,285,011, while during the 10 months period
after the introduction of daily fee it decreased to 1.940.880. The
average monthly number of admissions was 207,728 before and
176,444 after the introduction of daily fee. This represents a
15.1% decrease in the number of acute care admissions. CON-
CLUSIONS: The introduction of hospital daily fee in the Hun-
garian inpatient care resulted in a signiﬁcant decrease of acute
inpatient care admissions. However we do not have information
whether admissions failed to be realized were really unnecessary
or not. Other elements of the health care reforms could have also
inﬂuenced the number of admissions.
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OBJECTIVES: On the 15th of February 2007 new forms of
co-payment were introduced in Hungary: visit fee (300 HUF/
visit) in the outpatient care and hospital daily fee (300 HUF/day)
in the inpatient care. The aim of this study is to analyze the effect
of the introduction of visit fee on the number of patient-visits to
outpatient care departments in Hungary. METHODS: The data
derive from the ﬁnancial database of the National Health Insur-
ance Fund Administration (OEP) of Hungary covering the period
of 2006–2008. We analyzed the number of patient visits during
a 10 months period before (from March 2006 to January 2007)
and after (from March 2007 to January 2008) the introduction
of visit fee. Data from February 2007 were omitted. RESULTS:
During the 10 months period before the introduction of visit fee
the total number of visits was 64,309,067, while during the 10
months period after the introduction of visit fee it decreased to
51.927.150. The average monthly number of outpatient visits
was 5,846,279 before and 4,720,650 after the introduction of
visit fee. This represents a 19.3% decrease in the number of
outpatient visits. CONCLUSIONS: The introduction of visit fee
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